Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE

ABACAVIR;DOLUTEGRAVIR;LAMIVUDINE

Standard Dose
600MG;50MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE is listed in Drugs@FDA under application 216223 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;DOLUTEGRAVIR;LAMIVUDINE Form and strength TABLET;ORAL - 600MG;50MG;300MG Sponsor LAURUS LABS LTD Submission history Latest submission status date: 2022-08-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE is listed in Drugs@FDA under application 216223 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;DOLUTEGRAVIR;LAMIVUDINE Form and strength TABLET;ORAL - 600MG;50MG;300MG Sponsor LAURUS LABS LTD Submission history Latest submission status date: 2022-08-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE (ABACAVIR;DOLUTEGRAVIR;LAMIVUDINE) | Drug Monograph | MedicHelpline